MedElevator
Войти в исследования JCO oncology practice · 2025
Under-Representation of Black and Hispanic Men in Metastatic Castration-Resistant Prostate Cancer Trials (2005-2021): A Call to Action.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dirican Canan D, Patel Sagar, Al Mardini Anas, Sofia Amara, Fernandes Bolivia Aloysia Crocete, Gondhi Venkatesh, Maroules Michael
Аннотация
PURPOSE: Black men face the highest incidence and mortality rates of prostate cancer globally, including a disproportionate burden of metastatic castration-resistant prostate cancer (mCRPC). Despite this, clinical trials often fail to adequately represent the populations most affected. This study evaluates representation trends in mCRPC trials over a 17-year period.
MATERIALS AND METHODS: We analyzed 33 phase III and IV mCRPC trials (2005-2021) registered on ClinicalTrials.gov. Data on race, ethnicity, and trial geography were extracted. Representation trends were assessed across time intervals and funding sources. A random-effects model was used to analyze pooled participant demographics.
RESULTS: Of 33 trials (n = 28,746), 73% reported race and 42% reported ethnicity. Among trials with available data, 79.2% of participants were White, 10.8% were Asian, and only 3.8% were Black or African American. Hispanic participation was 6.7%. Notably, Black participation declined from 13.7% to 3% over the study period. Trial sites were predominantly located in North America and Europe, with no inclusion from Africa or the Caribbean.
CONCLUSION: Racial and ethnic under-representation in mCRPC trials has remained profound and, in some cases, worsened, despite increasing awareness. These findings underscore a critical need for structural reforms in trial design, funding, and regulatory oversight to ensure equitable access and generalizability of prostate cancer therapies.
MATERIALS AND METHODS: We analyzed 33 phase III and IV mCRPC trials (2005-2021) registered on ClinicalTrials.gov. Data on race, ethnicity, and trial geography were extracted. Representation trends were assessed across time intervals and funding sources. A random-effects model was used to analyze pooled participant demographics.
RESULTS: Of 33 trials (n = 28,746), 73% reported race and 42% reported ethnicity. Among trials with available data, 79.2% of participants were White, 10.8% were Asian, and only 3.8% were Black or African American. Hispanic participation was 6.7%. Notably, Black participation declined from 13.7% to 3% over the study period. Trial sites were predominantly located in North America and Europe, with no inclusion from Africa or the Caribbean.
CONCLUSION: Racial and ethnic under-representation in mCRPC trials has remained profound and, in some cases, worsened, despite increasing awareness. These findings underscore a critical need for structural reforms in trial design, funding, and regulatory oversight to ensure equitable access and generalizability of prostate cancer therapies.